Minerva Neurosciences | NERV - Ordinary Share Capital


Minerva Neurosciences reported $1000 in Ordinary Share Capital for its fiscal quarter ending in September of 2024.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 172.31M 174K Sep/2026
Adma Biologics USD 225.36M 6.93M Jun/2026
ALKERMES USD 168.03M 489K Sep/2026
Alterity Therapeutics Limited AUD 10.88B 10.66B Dec/2025
AstraZeneca USD 1.55B 28K Sep/2026
BioCryst Pharmaceuticals USD 255.26M 42.2M Jun/2026
Bristol-Myers Squibb USD 2.04B 7M Jun/2026
Cipla INR 807.87M 88K Sep/2026
Clal Biotechnology ILS 1.61M 0 Dec/2022
Compugen USD 94.72M 170K Jun/2026
CSL USD 482.13M 93.87M Dec/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
GlaxoSmithKline GBP 2.02B 2.05B Sep/2026
Grifols EUR 680.58M 846.11K Dec/2025
Halozyme Therapeutics USD 113.94M 106K Sep/2026
Ionis Pharmaceuticals USD 165.64M 265K Jun/2026
J&J USD 2.41B 1.64M Jun/2026
Merck USD 2.47B 1.05M Jun/2026
Minerva Neurosciences USD 1000 0 Sep/2024
Neurocrine Biosciences USD 101.3M 750K Sep/2026
Novartis USD 1.89B 12.09M Sep/2026
Novavax USD 162.58M 106K Dec/2025
Pfizer USD 5.7B 0 Jun/2026
Roche Holding CHF 796.77M 1.15M Jun/2026
Sanofi EUR 1.2B 0 Sep/2026
Takeda JPY 1.58B 460K Jun/2026
Vanda Pharmaceuticals USD 58K 0 Dec/2024